| ID | 69959 |
| FullText URL | |
| Author |
Ahn, Myung-Ju
Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine
Cho, Byoung Chul
Medical Oncology Department-501, ABMRC, Yonsei University
Ohashi, Kadoaki
Department of Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
researchmap
Izumi, Hiroki
Thoracic Oncology, National Cancer Center Hospital East
Lee, Jong-Seok
Hematology/Oncology, Seoul National University Bundang Hospital
Han, Ji-Youn
Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy
Chiang, Chi-Lu
Department of Chest Medicine, Taipei Veterans General Hospital
Huang, Shuang
Amgen Inc.
Hamidi, Ali
Amgen Inc.
Mukherjee, Sujoy
Amgen Inc.
Xu, Krista Lin
Amgen Asia Pacific Pte. Ltd.
Akamatsu, Hiraoki
Internal Medicine III, Wakayama Medical University
|
| Abstract | Introduction: Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.
Methods: Patients with previously treated, advanced SCLC received 10 mg tarlatamab every 2 weeks. The primary endpoint was objective response rate (ORR) by blinded independent central review (RECIST version 1.1). Key secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. The present analysis includes patients enrolled at sites in Asia. Results: A total of 43 patients were enrolled at sites in Asia. ORR was 46.3% (95% confidence interval [CI], 30.7–62.6) and median DOR was 7.2 months (95% CI 3.9 to not estimable). The median follow-up was 16.6 months for PFS and 21.2 months for OS. Median PFS was 5.4 months (95% CI 3.0–8.1) and median OS was 19.0 months (95% CI 11.4 to not estimable). The most common treatment-emergent adverse event (AE) was cytokine release syndrome (48.8%), and all such events were grade 1 or 2. There were no discontinuations due to treatment-related AEs. Conclusions: Tarlatamab demonstrated durable responses and promising survival outcomes with a manageable safety profile in this post hoc analysis of patients from Asia with previously treated SCLC. Trial Registration: ClinicalTrials.gov, NCT05060016. |
| Keywords | Small cell lung cancer (SCLC)
Tarlatamab
DLL3
Bispecific T-cell engager
Asian patients
|
| Published Date | 2025-09-04
|
| Publication Title |
Oncology and Therapy
|
| Volume | volume13
|
| Issue | issue4
|
| Publisher | Springer Science and Business Media LLC
|
| Start Page | 1041
|
| End Page | 1054
|
| ISSN | 2366-1070
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | © The Author(s) 2025
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| Related Url | isVersionOf https://doi.org/10.1007/s40487-025-00372-0
|
| License | http://creativecommons.org/licenses/by-nc/4.0/
|
| Citation | Ahn, MJ., Cho, B.C., Ohashi, K. et al. Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer. Oncol Ther 13, 1041–1054 (2025). https://doi.org/10.1007/s40487-025-00372-0
|
| 助成情報 |
( Amgen Inc. )
|